Low-dose tirofiban is associated with reduced in-hospital mortality in cardioembolic stroke patients treated with endovascular thrombectomy


      • Approximate 40% cardioembolic stroke patients treated with EVT received tirofiban.
      • Low-dose tirofiban is not associated with symptomatic intracerebral hemorrhage.
      • In-hospital mortality was significantly lower in patients receiving low-dose tirofiban.


      Background and purpose

      Whether tirofiban is safe and effective in cardioembolic stroke patients treated with endovascular thrombectomy (EVT) remains unknown; this study evaluated the safety and efficacy of low-dose tirofiban in this patients population.


      This study was a prospective registry study. Patients with cardioembolic stroke undergoing EVT from January 2013 to December 2020 were treated with EVT alone or EVT plus low-dose tirofiban. The primary outcome was symptomatic intracerebral hemorrhage (sICH) prior to discharge. The secondary outcomes included reocclusion, in-hospital mortality, and 3-month functional outcomes.


      Overall, 288 patients were recruited and 117 received low-dose tirofiban; 137 patients (47.6%) experienced ICH, 42 patients (14.6%) were sICH, and 23 patients (8%) were fatal ICH. Thirteen patients (11.1%) receiving tirofiban and 29 patients (17.0%) not receiving tirofiban experienced sICH (p = 0.167). Reocclusion occurred in nine patients (7.7%) receiving tirofiban and 15 patients (8.8%) not receiving tirofiban (p = 0.745). The rates of hernia (6.8% versus 20.5%) and decompressive craniectomy (2.6% versus 11.7%) were significantly lower in patients receiving tirofiban (p < 0.01). At 3-month follow-up, functional independence was achieved in 39 patients(33.3%) receiving tirofiban and 43 patients (25.1%) not receiving tirofiban (p = 0.131). Tirofiban was associated with lower odds of in-hospital mortality (3.4% versus 12.3%; adjusted odds ratio, 0.16; 95% confidence interval, 0.03–0.81; adjusted p = 0.027).


      In patients with cardioembolic stroke undergoing EVT, tirofiban is not associated with higher sICH, it seems to lead to lower odds of in-hospital death. Further investigations are needed to confirm these results and to determine the optimal treatment protocols of tirofiban.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tsivgoulis G.
        • Safouris A.
        • Katsanos A.H.
        • Arthur A.S.
        • Alexandrov A.V.
        Mechanical thrombectomy for emergent large vessel occlusion: a critical appraisal of recent randomized controlled clinical trials.
        Brain Behav. 2016; 6e00418
        • Campbell B.C.
        • Hill M.D.
        • Rubiera M.
        • Menon B.K.
        • Demchuk A.
        • Donnan G.A.
        • et al.
        Safety and efficacy of solitaire stent thrombectomy: individual patient data meta-analysis of randomized trials.
        Stroke. 2016; 47: 798-806
        • Abraham P.
        • Scott Pannell J.
        • Santiago-Dieppa D.R.
        • Cheung V.
        • Steinberg J.
        • Wali A.
        • et al.
        Vessel wall signal enhancement on 3-T MRI in acute stroke patients after stent retriever thrombectomy.
        Neurosurg. Focus. 2017; 42E20
        • Fu Z.
        • Xu C.
        • Liu X.
        • Wang Z.
        • Gao L.
        Safety and efficacy of tirofiban in acute ischemic stroke patients receiving endovascular treatment: a meta-analysis.
        Cerebrovasc. Dis. 2020; 49: 442-450
        • Kim Y.W.
        • Sohn S.I.
        • Yoo J.
        • Hong J.H.
        • Kim C.H.
        • Kang D.H.
        • et al.
        Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study.
        BMC Neurol. 2020; 20: 284
        • Yan Z.
        • Shi Z.
        • Wang Y.
        • Zhang C.
        • Cao J.
        • Ding C.
        • et al.
        Efficacy and safety of low-dose tirofiban for acute intracranial atherosclerotic stenosis related occlusion with residual stenosis after endovascular treatment.
        J. Stroke Cerebrovasc. Dis. 2020; 29: 104619
        • Mehndiratta M.M.
        • Khan M.
        • Mehndiratta P.
        • Wasay M.
        Stroke in Asia: geographical variations and temporal trends.
        J. Neurol. Neurosurg. Psychiatry. 2014; 85: 1308-1312
        • Ferro J.M.
        Cardioembolic stroke: an update.
        Lancet Neurol. 2003; 2: 177-188
        • Sun Y.
        • Guo Z.N.
        • Yan X.
        • Wang M.
        • Zhang P.
        • Qin H.
        • et al.
        Safety and efficacy of tirofiban combined with endovascular therapy compared with endovascular therapy alone in acute ischemic stroke: a meta-analysis.
        Neuroradiology. 2021; 63: 17-25
        • Zhao W.
        • Che R.
        • Shang S.
        • Wu C.
        • Li C.
        • Wu L.
        • et al.
        Low-dose tirofiban improves functional outcome in acute ischemic stroke patients treated with endovascular thrombectomy.
        Stroke. 2017; 48: 3289-3294
        • Kellert L.
        • Hametner C.
        • Rohde S.
        • Bendszus M.
        • Hacke W.
        • Ringleb P.
        • et al.
        Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome.
        Stroke. 2013; 44: 1453-1455
        • Zhao W.
        • Shang S.
        • Li C.
        • Wu L.
        • Wu C.
        • Chen J.
        • et al.
        Long-term outcomes of acute ischemic stroke patients treated with endovascular thrombectomy: a real-world experience.
        J. Neurol. Sci. 2018; 390: 77-83
        • Adams Jr., H.P.
        • Bendixen B.H.
        • Kappelle L.J.
        • Biller J.
        • Love B.B.
        • Gordon D.L.
        • et al.
        Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in Acute Stroke Treatment.
        Stroke. 1993; 24: 35-41
        • Mikulik R.
        • Ribo M.
        • Hill M.D.
        • Grotta J.C.
        • Malkoff M.
        • Molina C.
        • et al.
        Accuracy of serial National Institutes of Health Stroke Scale scores to identify artery status in acute ischemic stroke.
        Circulation. 2007; 115: 2660-2665
        • Barber P.A.
        • Demchuk A.M.
        • Zhang J.
        • Buchan A.M.
        Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke programme Early CT Score.
        Lancet. 2000; 355: 1670-1674
        • Hacke W.
        • Kaste M.
        • Bluhmki E.
        • Brozman M.
        • Davalos A.
        • Guidetti D.
        • et al.
        Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
        N. Engl. J. Med. 2008; 359: 1317-1329
        • Von Kummer R.
        • Broderick J.P.
        • Campbell B.C.V.
        • Demchuk A.M.
        • Goyal M.
        • Hill M.D.
        • et al.
        The Heidelberg bleeding classification classification of bleeding events after ischemic stroke and reperfusion therapy.
        Stroke. 2015; 46: 2981-2986
        • Glantz S.A.
        • Slinker B.K.
        Primer of Applied Regression and Analysis of Variance.
        Primer of Applied Regression & Analysis of Variance, 1990
        • Montalvo M.
        • Mistry E.
        • Chang A.D.
        • Yakhkind A.
        • Dakay K.
        • Azher I.
        • et al.
        Predicting symptomatic intracranial haemorrhage after mechanical thrombectomy: the TAG score.
        J. Neurol. Neurosurg.: Psychiatry. 2019; 90: 1370-1374
        • Yang M.
        • Huo X.
        • Miao Z.
        • Wang Y.
        Platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke.
        Drugs. 2019; 79: 515-529
        • Sun C.
        • Li X.
        • Zhao Z.
        • Chen X.
        • Huang C.
        • Li X.
        • et al.
        Safety and efficacy of tirofiban combined with mechanical thrombectomy depend on ischemic stroke etiology.
        Front. Neurol. 2019; 10: 1100
        • Zhang S.
        • Hao Y.
        • Tian X.
        • Zi W.
        • Wang H.
        • Yang D.
        • et al.
        Safety of intra-arterial tirofiban administration in ischemic stroke patients after unsuccessful mechanical thrombectomy.
        J. Vasc. Interv. Radiol. : JVIR. 2019; 30 (141-7.e1)
        • Maïer B.
        • Desilles J.P.
        • Mazighi M.
        Intracranial hemorrhage after reperfusion therapies in acute ischemic stroke patients.
        Front. Neurol. 2020; 11: 599908
        • Choudhri T.F.
        • Hoh B.L.
        • Zerwes H.G.
        • Prestigiacomo C.J.
        • Kim S.C.
        • Jr C.E.
        • et al.
        Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.
        J. Clin. Investig. 1998; 102: 1301